Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical Company Limited announced the successful approval of their Supplementary Drug Application for diazepam tablets by the National Medical Products Administration. This milestone approval allows the transfer of marketing authorization for the product, which follows a technology transfer contract with Jilin Xianfeng Technology Pharmaceutical Co., Ltd. The company confirms the accuracy and completeness of the announcement without any false or misleading statements.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
